INAB Historical PE Ratio Notes

— IN8bio (ticker symbol INAB) is a clinical-stage biotechnology company focused on developing novel therapies for cancer, specifically using innovative gamma-delta T cell therapies that harness the immune system to target & destroy cancer cells. IN8bio's scientific platform is highly specialized, aiming to treat both solid & hematologic tumors, which places the company in the high-risk, high-reward segment of healthcare. This business model has significant implications for its historical price-to-earnings (PE) ratio: like many early-stage biotech firms, IN8bio has historically generated little or no revenue, let alone positive earnings. Investors reviewing historical PE ratio charts for INAB should expect to see very high numbers (or a lack of meaningful PE data) during periods of net losses or nascent revenue streams. This is typical for pre-commercial biotech companies, because the market price reflects investor optimism about future breakthroughs, rather than current profits. Therefore, historical PE ratios for INAB likely tell you more about expectations for future clinical progress & eventual commercialization, rather than current operational performance. Understanding this will help you contextualize PE ratio trends as you analyze IN8bio's financial history.

On this page we presented the INAB Historical PE Ratio information for IN8bio' stock. The average INAB historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average INAB historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this INAB historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for INAB had been 1.49, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on INAB or any other given stock, valuation analysis for INAB can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate IN8bio PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for INAB. Thanks for visiting, and the next time you need to research INAB Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.